Stocklytics Platform
Asset logo for symbol RXST
High Growth
Asset logo for symbol RXST


Key Stats
Prev. Close$47.22
Next Earnings Date-
Dividend Yield %-
PE Ratio-
Day Range45.10
52 Week Range20.66
Payout Ratio-
Industry average yield2.83%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_down1.07%
US Marketarrow_drop_down1.14%
RXST / Market
RXST lose to the US Market which returned -1.14% over the last twenty four hours.
RXST / Healthcare Sector
RXST lose to the US Healthcare sector which returned -1.07% over the last twenty four hours.

RxSight (RXST) Statistics

RxSight, Inc. (NASDAQ: RXST) is a medical technology company that specializes in the development and commercialization of innovative products for the treatment of eye diseases. With a focus on providing customized solutions, RxSight aims to improve patient outcomes and enhance the quality of life for individuals suffering from vision impairments. The company's flagship product is the RxSight Light Adjustable Lens (LAL), which offers a revolutionary approach to cataract surgery.

When it comes to valuing RxSight, Inc. (RXST) stock, investors can consider a range of metrics. One important metric is the stock's valuation multiples, such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio. These metrics can provide insights into the stock's relative value compared to its earnings, sales, and assets. Additionally, investors may also look at the company's fundamentals, including its revenue, earnings, and cash flow, to assess its financial health and growth potential.

add RxSight to watchlist

Keep an eye on RxSight

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has RxSight (RXST) stock's performance compared to its sector and the market over the past year?

Over the past year, RxSight (RXST) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.13%, RxSight has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.53%, it has fallen short of the market average. This comparison highlights RxSight's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of RxSight (RXST) stock?

The PE ratio for RxSight (RXST) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of RxSight (RXST) stock?

The Earnings Per Share (EPS) for RxSight (RXST), calculated on a diluted basis, is -$1.24. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of RxSight (RXST) stock?

The operating margin for RxSight (RXST) is -36.15%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of RxSight (RXST) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of RxSight (RXST) is -$43.42M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does RxSight (RXST) have?

RxSight (RXST) has a total debt of $2.52M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$30.12M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level